Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3586090
Max Phase: Preclinical
Molecular Formula: C17H20F3N5S2
Molecular Weight: 415.51
Molecule Type: Small molecule
Associated Items:
ID: ALA3586090
Max Phase: Preclinical
Molecular Formula: C17H20F3N5S2
Molecular Weight: 415.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CN=C(N2CCN(c3ncnc4sc(CC(F)(F)F)cc34)CC2)S1
Standard InChI: InChI=1S/C17H20F3N5S2/c1-16(2)9-21-15(27-16)25-5-3-24(4-6-25)13-12-7-11(8-17(18,19)20)26-14(12)23-10-22-13/h7,10H,3-6,8-9H2,1-2H3
Standard InChI Key: SFDROHXKTATJBI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 415.51 | Molecular Weight (Monoisotopic): 415.1112 | AlogP: 3.80 | #Rotatable Bonds: 2 |
Polar Surface Area: 44.62 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 6.08 | CX LogP: 4.32 | CX LogD: 4.30 |
Aromatic Rings: 2 | Heavy Atoms: 27 | QED Weighted: 0.75 | Np Likeness Score: -1.44 |
1. Senter T, Gogliotti RD, Han C, Locuson CW, Morrison R, Daniels JS, Cierpicki T, Grembecka J, Lindsley CW, Stauffer SR.. (2015) Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility., 25 (13): [PMID:25987377] [10.1016/j.bmcl.2015.04.026] |
2. Pollock J, Borkin D, Lund G, Purohit T, Dyguda-Kazimierowicz E, Grembecka J, Cierpicki T.. (2015) Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes., 58 (18): [PMID:26288158] [10.1021/acs.jmedchem.5b00975] |
3. Chen QB, Gao J, Zou GA, Xin XL, Aisa HA.. (2018) Piperidine Alkaloids with Diverse Skeletons from Anacyclus pyrethrum., 81 (6): [PMID:29775308] [10.1021/acs.jnatprod.8b00239] |
4. Jedwabny W, Kłossowski S, Purohit T, Cierpicki T, Grembecka J, Dyguda-Kazimierowicz E.. (2017) Theoretical models of inhibitory activity for inhibitors of protein-protein interactions: targeting menin-mixed lineage leukemia with small molecules., 8 (12): [PMID:29456828] [10.1039/C7MD00170C] |
5. Wang X, Su M, Li Y, Liu T, Wang Y, Chen Y, Tang L, He YP, Ding X, Yu F, Shen J, Li J, Zhou Y, Chen YL, Xiong B.. (2019) Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor., 29 (6): [PMID:30713023] [10.1016/j.bmcl.2019.01.017] |
6. Ren J, Xu W, Tang L, Su M, Chen D, Chen YL, Zang Y, Li J, Shen J, Zhou Y, Xiong B.. (2016) Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface., 26 (18): [PMID:27528435] [10.1016/j.bmcl.2016.07.074] |
Source(1):